A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
Launched by LUX BIOSCIENCES, INC. · Nov 27, 2006
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Documented history of non-infectious anterior, anterior and intermediate- or panuveitis
- • Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy due to the development of an ocular hypertensive response or subjects for whom oral corticosteroid is contraindicated.
- • Grade of 2+ or higher for anterior chamber cells at time of enrollment
- • Considered by the investigator to require corticosteroid-sparing therapy.
- • Subjects not planning to undergo elective ocular surgery during the study
- Exclusion Criteria:
- • Uveitis of infectious etiology
- • Presence of an ocular toxoplasmosis scar
- • An immune suppression regimen that includes an alkylating agent within the previous 90 days
About Lux Biosciences, Inc.
Lux Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in the field of ophthalmology. With a commitment to advancing eye care, Lux Biosciences leverages cutting-edge research and clinical expertise to create novel treatments for various ocular conditions. The company is dedicated to enhancing patients' quality of life through the development of safe and effective therapies, with an emphasis on rigorous clinical trial methodologies and a patient-centered approach. Their portfolio includes products aimed at improving vision and managing diseases that significantly impact eye health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Birmingham, Alabama, United States
Portland, Oregon, United States
Chicago, Illinois, United States
Baltimore, Maryland, United States
Montreal, Quebec, Canada
Phoenix, Arizona, United States
Cambridge, Massachusetts, United States
Grand Rapids, Michigan, United States
Kansas City, Missouri, United States
New York, New York, United States
Durham, North Carolina, United States
San Antonio, Texas, United States
Norfolk, Virginia, United States
Salzburg, , Austria
Wien, , Austria
Paris, , France
Freiburg, , Germany
Heidelberg, , Germany
Tübingen, , Germany
Hyderabaad, Andhra Pradesh, India
Madurai, Tamil Nadu, India
Bangalore, , India
Chandigarh, , India
Coimbatore, , India
Mumbai, , India
Bristol, , United Kingdom
Liverpool, , United Kingdom
Austin, Texas, United States
Münster, , Germany
Patients applied
Trial Officials
Eddy Anglade, M.D.
Study Chair
Chief Medical Officer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials